Outsourcing in Clinical Trials Nordics 201417-18 September 2014, Copenhagen, Denmark
The OCT team would like to thank you for making the 2013 launch event such a huge success.
In September this year close to 200 industry professionals attended our first Outsourcing in Clinical Trials Nordics event to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical challenges.
Covering a broad range of content related to all aspects of clinical outsourcing from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques, this year’s agenda boasted presentations, case studies, panel discussions and roundtables all presented and facilitated by a high calibre speaking faculty local to this industry hub.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within biotechnology, pharmaceutical, virtual and medical device companies throughout the Nordic region.
Outsourcing in Clinical Trials Nordics boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
C3 Jian has initiated the first Phase II clinical study for its C16G2, which selectively targets a cavity-causing organism Streptococcus mutans, under its US Food and Drug Administration investigational new drug (IND) application.
BioLineRx has completed the dose-escalation stage of the ongoing Phase I/II clinical study for BL-7010, a non-absorbable, orally available polymer intended for treatment of celiac disease.
Novartis has announced that the Phase III study of Jakavi (ruxolitinib) has met its primary endpoint of maintaining haematocrit control (red blood cell volume) without the need for phlebotomy and reducing spleen size in patients with polycythemia ver…
Ireland-based biopharmaceutical firm Alkermes has started a major clinical development programme for ALKS 5461, a once-daily, oral investigational medicine with a new mechanism of action for the adjunctive treatment of major depressive disorder (MDD)…
Israel-based Kamada has started a Phase II/III clinical study of its proprietary human Alpha-1 Antitrypsin (AAT) 'Glassia' for the treatment of newly diagnosed paediatric patients with type 1 diabetes (T1D).
US-based Regulus Therapeutics has started dosing of RG-101, a sGalNAc-conjugated anti-miR targeting microRNA-122 (miR-122), in healthy subjects in a Phase I clinical study.